Santen Pharmaceutical | Sustainability Performance

https://www.santen.com/

Pharmaceutical company specializing in ophthalmic products and treatments.

1890

Japan

1,001 - 5,000 employees

Pharmaceuticals

$1B - 10B in revenue

$100M - 500M in profitability

Submit or report inaccurate data Download Company Insights

Sustainability Ranking & Industry Benchmark

#7411

Overall

#316

in Japan

#174

in Pharmaceuticals

Sustainability Maturity

Sustainability Intent

Available in
Scale package

Access

Industry Rank

100 out of 312

Overview

Environmental

Carbon emissionsEnergy consumptionWaste managementWater managementAir and land impactNature and biodiversityNature riskClimate risk

Social

Diversity and inclusionPay gapsHealth and safetyExternalities

Governance

TargetsSDG ImpactESG scores and exclusionsB-corp & CDP

Financial Data

Business performanceCapital & innovationAnalyst projections

View similiar companies

Rici Healthcare

Japan, Hospital & Health Care, Hospital & Health Care

Takeda Pharmaceutical

Japan, Hospital & Health Care, Pharmaceuticals

Sumitomo Pharma

Japan, Hospital & Health Care, Pharmaceuticals

CO2 scope 1 + 2

52.9K CO2e tonnes, 2025

Laggard

Renewable energy

17% 2025

Laggard

Waste generated

3.3K tonnes, 2025

Aligned

Female engagement

49% 2024

Aligned

Externalities

4.0M $, 2025

Aligned

Market cap

93.3T $, 2026▲7% YoY

Revenue

1.9B $, 2026▼2.9% YoY

R&D intensity

8.98% 2026

Intensity

Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)

Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)

Energy consumption (direct) intensity (MWh /$M)

Water consumption intensity (m³ /$M)

Waste generation intensity (tonnes /$M)

Industry Benchmark

27.2

B/M 13.9

106.5

B/M 114.3

133.5

B/M 35.7

44.6

B/M 219.7

1.7

B/M 0.3

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Santen Pharmaceutical Co Ltd, Japanese ophthalmology major, has faced multiple US FDA Form 483 observations at multiple production facilities following the contested 2024 sustained share price volatility amid Asian ophthalmology customer demand normalization, plus periodic Japanese FSA enforcement scrutiny on inadequate disclosure of glaucoma drug customer concentration affecting Japanese institutional shareholders.

Carbon emissions breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Biodiversity impact

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Waste management

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	-	*******

Water management

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Air pollution

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Land use

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Diversity & inclusion

Reveal data for 3 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Pay gap breakdown

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	-	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	-	-	-	-	*******

Health & safety

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******

Externalities

Reveal data for 1 credit

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

SBTi targets and commitments

Target	Status	Temperature alignment	Year
Near-term target	Targets set	1.5°C	FY2030
Long-term target	Not disclosed	-	-
Net-zero	Not disclosed	-	-
Business Ambition 1.5°C	Not disclosed	-	-

Target details

Santen Pharmaceutical Co. , Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 50% by FY 2030 from a FY 2019 base year. Santen Pharmaceutical Co. , Ltd. also commits to reduce absolute scope 3 GHG emissions from purchased goods and services 15% within the same timeframe.

SDG impact (historical)

Reveal data for 5 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Reporting

Sustainability Report

Available

Sustainability employees

Total sustainability employees

Available in
Scale package

Access

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Santen Pharmaceutical Co Ltd, Japanese ophthalmology major, has faced multiple US FDA Form 483 observations at multiple production facilities following the contested 2024 sustained share price volatility amid Asian ophthalmology customer demand normalization, plus periodic Japanese FSA enforcement scrutiny on inadequate disclosure of glaucoma drug customer concentration affecting Japanese institutional shareholders.

Santen Pharmaceutical | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Carbon emissions

Renewable energy

Intensity

Female engagement

Waste

Controversy level

Carbon emissions breakdown

Climate risk

Nature risk

Production loss

Revenue at risk

Assets exposed to sensitive locations

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

SBTi targets and commitments

Target details

Overall score

Environment

Social

Governance

Exclusion screening

CDP Scores

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

Santen Pharmaceutical | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Carbon emissions

Renewable energy

Intensity

Female engagement

Waste

Controversy level

Carbon emissions breakdown

Climate risk

Nature risk

Production loss

Revenue at risk

Assets exposed to sensitive locations

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Available in
Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package